Claims
- 1. A compound of the formula: whereinRa represents (1-6C)alkyl, CO(1-6C)alkyl, CO(aryl), CO2(1-6C)alkyl, CO2(1-6C)alkylaryl, CO2(aryl), CO(1-6C)alkylNH(1-6C)alkyl, or CO(1-6C)alkylN(1-6C)alkyl2; R1 represents a naphthyl group or a phenyl group which is unsubstituted or substituted by one or two substituents selected independently from halogen; nitro; cyano; hydroxylmino; (1-10C)alkyl; (2-10C)alkenyl; (2-10C)alkynyl; (3-8C)cycloalkyl; hydroxy(3-8C)cycloalkyl; oxo(3-8C)cycloalkyl; halo(1-10C)alkyl; (CH2)yX1R9 in which y is 0 or an integer of from 1 to 4, X1 represents 0, S, NR10, CO, COO, OCO, CONR11, NR12CO, NR12COCOO or OCONR13, R9 represents hydrogen, (1-10C)alkyl, (3-10C)alkenyl, (3-10C)alkynyl, pyrrolidinyl, tetrahydrofuryl, morpholino or (3-8C)cycloalkyl and R10, R11, R12 and R13 each independently represents hydrogen or (1-10C)alkyl, or R9 and R10, R11, R12 or R13 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group; N-(1-4C)alkylpiperazinyl; N-phenyl(1-4C)alkylpiperazinyl; thienyl; furyl; oxazolyl; isoxazolyl; pyrazolyl; imidazolyl; thiazolyl; pyridyl; pyridazinyl; pyrimidinyl; dihydro-thienyl; dihydrofuryl; dihydrothiopyranyl; dihydropyranyl; dihydrothiazolyl; (1-4C)alkoxycarbonyldihydrothiazolyl; (1-4C)alkoxycarbonyldimethyldihydrothiazolyl; tetrahydro-thienyl; tetrahydrofuryl; tetrahydrothiopyranyl; tetrahydropyranyl; indolyl; benzofuryl; benzothienyl; benzimidazolyl; and a group of formula R14—(La)n—X2—(Lb)m in which X2 represents a bond, O, NH, S, SO, SO2, CO, CH(OH), CONH, NHCO, NHCONH, NHCOO, COCONH, OCH2CONH or CH═CH, La and Lb each represent (1-4C)alkylene, one of n and m is 0 or 1 and the other is 0, and R14 represents a phenyl or heteroaromatic group which is unsubstituted or substituted by one or two of halogen, nitro, cyano, hydroxylmino, (1-10C)alkyl, (2-10C)alkenyl, (2-10C)alkynyl, (3-8C)-cycloalkyl, 4-(1,1-dioxotetrahydro-1,2-thiazinyl), halo(1-10C)alkyl, cyano(2-10C)alkenyl, phenyl, and (CH2)zX3R15 in which z is 0 or an integer of from 1 to 4, X3 represents O, S, NR16, CO, CH(OH), COO, OCO, CONR17, NR18CO, NHSO2, NHSO2NR17, NHCONH, OCONR19 or NR19COO, R15 represents hydrogen, (1-10C)alkyl, phenyl(1-4C)alkyl, halo(1-10C)alkyl, (1-4C)alkoxycarbonyl(1-4C)alkyl, (1-4C)alkylsulfonylamino(1-4C)alkyl, (N-(1-4C)alkoxycarbonyl)(1-4C)alkylsulfonylamino-(1-4C)alkyl, (3-10C)alkenyl, (3-10C)alkynyl, (3-8C)-cycloalkyl, camphoryl or an aromatic or heteroaromatic group which is unsubstituted or substituted by one or two of halogen, (1-4C)alkyl, halo(1-4C)alkyl, di(1-4C)alkylamino and (1-4C)alkoxy and R16, R17, R18 and R19 each independently represents hydrogen or (1-10C)alkyl, or R15 and R16, R17, R18 or R19 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group; R2 represents ethyl, 2-propyl, or dimethylamino R5, R6 and R7 represent hydrogen; and R8 represents methyl; or a pharmaceutically acceptable salt thereof.
- 2. A compound according to claim 1 wherein Ra is (1-6C)alkyl, CO(1-6C)alkyl, CO(aryl), CO2(1-6C)alkyl, CO2(1-6C)alkylaryl, or CO2(aryl).
- 3. A compound according to claim 1 wherein Ra is (1-6C)alkyl.
- 4. A compound according to claim 1 wherein Ra is methyl.
- 5. A pharmaceutical composition, which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable diluent or carrier.
- 6. A method of potentiating glutamate receptor function in a mammal requiring such treatment, which comprises administering an effective amount of a compound of claim 1.
- 7. A method of treating a cognitive disorder; a neuro-degenerative disorder; age-related dementia; age-induced memory impairment; movement disorder; reversal of a drug-induced state; depression; attention deficit disorder; attention deficit hyperactivity disorder; psychosis; cognitive deficits associated with psychosis; or drug-induced psychosis in a patient, which comprises administering to a patient in need thereof an effective amount of a compound according to claim 1.
- 8. A method for improving memory or learning ability in a patient, which comprises administering to a patient in need thereof an effective amount of a compound according to claim 1.
Parent Case Info
This is a 371 of PCT/US99/17017 filed Jul. 28, 1999 which claims priority to U.S. Provisional Application No. 60/094,921 filed Jul. 31, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US99/17017 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/06537 |
2/10/2000 |
WO |
A |
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
4370328 |
Campbell et al. |
Jan 1983 |
A |
5962462 |
Mills et al. |
Oct 1999 |
A |
6174922 |
Arnold et al. |
Jan 2001 |
B1 |
6355655 |
Escribano et al. |
Mar 2002 |
B1 |
6358982 |
Cantrell et al. |
Mar 2002 |
B1 |
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO 9833496 |
Feb 1997 |
WO |
WO0006083 |
Feb 2000 |
WO |
WO0006148 |
Feb 2000 |
WO |
Non-Patent Literature Citations (1)
Entry |
Barker et al., Dehalogenation of 1-Halogenothienyl-di- and -tetra-hydroisoquinolines by Sodium Methoxide in Dimethyl Sulphoxide, J. Chem. Soc. Perkin Trans. I, No. 2, pp. 275-281, Feb. 1985. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/094921 |
Jul 1998 |
US |